Who are omega-3 fatty acids (fish oil)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epanova, Palmitoleic Acid + Infliximab, Trimetazidine mimic, LOVAZA Omega 3-acid ethyl esters, Omacor + simvastatin, Antara (fenofibrate) + Lovaza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omega-3-fatty-acids-fish-oil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

omega-3 fatty acids (fish oil) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

omega-3 fatty acids (fish oil) (omega-3 fatty acids (fish oil)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fatty acid. Area: Cardiovascular.

phase 3 Fatty acid Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

omega-3 fatty acids (fish oil) (omega-3 fatty acids (fish oil)) — Brigham and Women's Hospital. Omega-3 fatty acids (fish oil) help reduce inflammation and improve heart health by modulating the body's response to fatty acids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
omega-3 fatty acids (fish oil) TARGET	omega-3 fatty acids (fish oil)	Brigham and Women's Hospital	phase 3	Fatty acid
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
Palmitoleic Acid + Infliximab	Palmitoleic Acid + Infliximab	Chinese Medical Association	marketed	TNF-α inhibitor + fatty acid combination	TNF-α receptor (via infliximab); GPR120 and other metabolic sensors (via palmitoleic acid)
Trimetazidine mimic	Trimetazidine mimic	Shenyang Northern Hospital	marketed	Metabolic modulator; fatty acid oxidation inhibitor	LC3KAT (long-chain 3-ketoacyl-CoA thiolase)
LOVAZA Omega 3-acid ethyl esters	LOVAZA Omega 3-acid ethyl esters	University of Michigan	marketed	Omega-3 fatty acid supplement
Omacor + simvastatin	Omacor + simvastatin	Provident Clinical Research	marketed	Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin)	VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)
Antara (fenofibrate) + Lovaza	Antara (fenofibrate) + Lovaza	GlaxoSmithKline	marketed	Fibrate + Omega-3 fatty acid combination	PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fatty acid class)

Brigham and Women's Hospital · 1 drug in this class
Federal University of São Paulo · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). omega-3 fatty acids (fish oil) — Competitive Intelligence Brief. https://druglandscape.com/ci/omega-3-fatty-acids-fish-oil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab